Close
Almac
Achema middle east

New Elsevier report highlights progress towards disease-modifying treatments for pancreatitis

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.

Smart Laboratories and the Rise of Connected Pharma Equipment Ecosystems

Connected equipment ecosystems revolutionize pharmaceutical operations by integrating AI-driven analytics, digital twins, and seamless middleware to enhance visibility, collaboration, and decision-making across the value chain.

Maximizing Portfolio Returns During Late-Stage Drug Development

Optimize late-stage pharmaceutical assets through strategic investment planning, risk management, and indication prioritization. Maximize R&D return on investment during the highest-stakes phase of drug development.
- Advertisement -

Elsevier, a global leader in research publishing and information analytics, has published the findings from a new report on emerging trends for pancreatitis in the scientific literature. Acute pancreatitis is the most common GI-related cause for hospitalization in the US; currently, there are no disease-modifying drugs available for the condition. The analysis was conducted with the aid of Natural Language Processing (NLP), which identified terms found to have the greatest increase in publication occurrences in pancreatitis literature over the past three years. The report examines the emergence of trending terms in the taxonomy categories ‘Biological Functions’ and ‘Proteins and Genomic Elements’, as well as compounds used in animal models and/or the clinic to interrogate potential therapeutic targets.

The terms in the proteins and genomic elements taxonomy category identified as trending (i.e., found within the literature with increasing frequency) were NLRP3, miR-155, and heme oxygenase (HO-1). Several drugs are in early clinical trials targeting the NLRP3 inflammasome for other inflammatory diseases – including Inzolemid from Inflazome (NCT04015076), DFV890 from Novartis (NCT04382053 & NCT04868968), NT-1067 from NodThera, and Dapansutrile from Olatec (NCT03534297, EudraCT 2016-000943-14, & NCT04540120).

“Identifying proteins and genes that are shown to be linked to pancreatitis is crucial to improving diagnostics and discovering potential drugs targets for a disease with few treatment options”, comments Dr Eric Gilbert, consultant at Elsevier and author of the report. “By taking advantage of NLP and Elsevier’s access to the vast scientific literature, insights can be uncovered that would be hard to obtain otherwise.”

Further findings from the report include:

  • A Chinese herbal medicine approved for heart failure in China was found to upregulate HO-1 in rats with induced severe acute pancreatitis. The treated rats showed protection against inflammatory organ damage.
  • Trending terms identified in the Biological Functions taxonomy category were neutrophil extracellular trap (NET) formation and polarization.
  • All of the terms discussed have been validated as potential targets by demonstrating positive impacts on pancreatitis biomarkers in in vivo animal models.

As the volume and variety of scientific research continues to grow, conducting reports like this helps refocus the industry on the trends that are most likely to lead to breakthroughs. They are also a valuable tool: for showing key stakeholders that the industry is making progress towards treatments, to identify potential research partners and collaborators, and to attract new funding to the area.

The full report from Elsevier’s Professional Services group looks at ongoing pancreatitis R&D, the biology and mechanisms of the disease, general knowledge gaps, and potential therapeutics. Access and download the report for free: Emerging Trends for Pancreatitis in the Scientific Literature.

Latest stories

Related stories

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.

Smart Laboratories and the Rise of Connected Pharma Equipment Ecosystems

Connected equipment ecosystems revolutionize pharmaceutical operations by integrating AI-driven analytics, digital twins, and seamless middleware to enhance visibility, collaboration, and decision-making across the value chain.

Maximizing Portfolio Returns During Late-Stage Drug Development

Optimize late-stage pharmaceutical assets through strategic investment planning, risk management, and indication prioritization. Maximize R&D return on investment during the highest-stakes phase of drug development.

India Outpaces Global Average With 2026 Medical Trend at 11.5 Percent: Aon Reports

Cardiovascular diseases, gastrointestinal conditions and cancer are top medical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »